1446358-48-0Relevant articles and documents
Discovery of CYR715: A novel carboxylic acid-containing soluble guanylate cyclase stimulator
Rennie, Glen R.,Barden, Timothy C.,Bernier, Sylvie G.,Carvalho, Andrew,Deming, Renee,Germano, Peter,Hudson, Colleen,Im, G-Yoon J.,Iyengar, Rajesh R.,Jia, Lei,Jung, Joon,Kim, Elise,Lee, Thomas W.-H.,Mermerian, Ara,Moore, Joel,Nakai, Takashi,Perl, Nicholas R.,Tobin, Jenny,Zimmer, Daniel P.,Renhowe, Paul A.
, (2021/03/22)
Soluble guanylate cyclase (sGC) is a clinically validated therapeutic target in the treatment of pulmonary hypertension. Modulators of sGC have the potential to treat diseases that are affected by dysregulation of the NO-sGC-cGMP signal transduction pathw
SOLID DISPERSIONS COMPRISING A SGC STIMULATOR
-
, (2017/06/27)
The present invention relates to solid dispersions of amorphous 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)propan-2-ol (Compound I) or a pharmaceutically acceptable salt thereof. It also relates to pharmaceutical compositions and pharmaceutical oral dosage unit forms comprising them, and their uses thereof.
Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans
Nakai, Takashi,Perl, Nicholas R.,Barden, Timothy C.,Carvalho, Andrew,Fretzen, Angelika,Germano, Peter,Im, G-Yoon J.,Jin, Hong,Kim, Charles,Lee, Thomas W.-H.,Long, Kimberly,Moore, Joel,Rohde, Jason M.,Sarno, Renee,Segal, Chrissie,Solberg, Erik O.,Tobin, Jenny,Zimmer, Daniel P.,Currie, Mark G.
supporting information, p. 465 - 469 (2016/06/01)
In recent years, soluble guanylate cyclase (sGC, EC 4.6.1.2) has emerged as an attractive therapeutic target for treating cardiovascular diseases and diseases associated with fibrosis and end-organ failure. Herein, we describe our design and synthesis of